Description

Membral (memantine) Coated Tablets 10 mg. №60

Ingredients

Active ingredient: Memantine hydrochloride. Inactive ingredients: microcrystalline cellulose, colloidal silicon dioxide, talc, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol.

Dosage

Recommended dosage: The usual starting dose is 5 mg once daily. The dose is then increased by 5 mg each week. The maximum recommended dose is 20 mg per day, taken in divided doses.

Indications

Membral (memantine) Coated Tablets are indicated for the treatment of moderate to severe Alzheimer’s disease.

Contraindications

Do not use Membral (memantine) Coated Tablets if: allergic to memantine or any other ingredients in the product, have severe kidney problems, or are pregnant or breastfeeding.

Directions

Take Membral (memantine) Coated Tablets exactly as prescribed by your healthcare provider. Swallow the tablets whole with water. Do not crush or chew the tablets.

Scientific Evidence

Studies have shown that memantine, the active ingredient in Membral tablets, can help improve cognitive function and slow the progression of Alzheimer’s disease. Research published in the Journal of Alzheimer’s Disease demonstrated that memantine treatment was associated with significant improvements in cognitive function and activities of daily living in patients with moderate to severe Alzheimer’s disease.

Additional Information

Membral (memantine) Coated Tablets have a good safety profile and are well-tolerated by most patients. Common side effects may include dizziness, headache, and constipation. It is important to follow up with your healthcare provider regularly while taking this medication.

Pharmacological Effects: Memantine works by regulating the activity of glutamate, a neurotransmitter involved in learning and memory. By blocking excessive glutamate activity, memantine helps protect brain cells from damage and improves cognitive function in Alzheimer’s patients.

Clinical Trials: Clinical trials have shown that memantine is effective in improving cognitive function, behavior, and overall functioning in patients with Alzheimer’s disease. A study published in the New England Journal of Medicine found that memantine treatment was associated with a slower rate of cognitive decline compared to a placebo.